CVS Health (CVS.US) Exceeds Expectations for Eight Consecutive Quarters, Plunges 12.5% Overnight After "One Becomes Two" Split! Why Doesn't the Split Lead to a Revaluation?

According to Zhitong Finance APP, on Wednesday CVS Health (CVS.US) announced it would split into two, while also delivering its eighth consecutive quarter of earnings beating expectations and providing 2027 profit guidance above Wall Street consensus. However, the market reacted in the opposite way: at the close overnight, the company's share price plunged 12.5%.

For a company that just "outperformed expectations," this is a rare valuation. Clearly, the market does not care about current profits; the real question is: after the split, what makes these two businesses more valuable?

According to the announcement, CVS will separate its retail pharmacy business from its Aetna insurance and Pharmacy Benefit Management (PBM) business, a transaction that essentially breaks apart the $117 billion healthcare conglomerate built over many years. The deal is expected to be completed in the first half of 2028, at which time CVS Health shareholders will own shares in both companies.

This also means that, for the first time since acquiring Caremark PBM in 2006, CVS’s retail pharmacy business will operate independently. Over the next two decades, the company engaged in a series of acquisitions, including buying Aetna for $78 billion in 2018.

The post-split structure has already been determined: CVS Health will continue to be led by current CEO David Joyner, overseeing Aetna, Caremark, specialty pharmacy, as well as healthcare service companies Oak Street Health and Signify Health. Prem Shah, currently responsible for pharmacy, related business, and healthcare service delivery, will become CEO of CVS Pharmacy, overseeing MinuteClinics, mail-order pharmacy, and the consumer platform called Health100—which leverages data across insurance companies, healthcare institutions, and pharmacies to help patients manage their healthcare.

Looking at the numbers, this was originally a report strong enough to support the stock price.

In Q3, the company reported earnings per share of $2.09, far above the LSEG analyst consensus estimate of $1.65—marking its eighth straight quarter beating Wall Street estimates. The company's adjusted EPS guidance for 2027 was set at not less than $8.65, also exceeding the analyst consensus of $8.53.

Management also emphasized fundamental improvements. Joyner stated that, over the past two years, the company’s 9,000-store pharmacy network, Caremark PBM operations, and Aetna insurance business have all significantly improved, making such a restructuring possible. "All segments are operating very well," he said in an interview. "We now have the ability to make different decisions—a flexibility I didn't have two years ago."

He recalled that, when he took over two years ago, the company anticipated the pharmacy business would decline by 5%. Since then, CVS upgraded store technology to boost capacity and adjusted prescription drug reimbursement models, allowing them to maintain profitability while offering lower prices for both branded and generic drugs. As for Aetna, previous miscalculations around the Medicare Advantage program for those over 65 meant financial targets were missed, but these have now been partly corrected.

Why hasn't this spin-off led to a re-rating?

First, and most directly: The spin-off plan lacks financial detail, making it impossible for investors to model.

Barclays analyst Andrew Mok explicitly listed “lack of financial detail around the split” as investors’ top concern. He reminded the market of a point of reference: Twenty years ago, when CVS acquired Caremark, they claimed at least $500 million in synergy gains from the transaction. By the same logic, a split would also result in lost synergies, but this time, the company has provided no quantification. How debt will be allocated between the two companies, how capital policies will be arranged, and how large the one-time split costs will be—these denominator issues for valuation models are all left blank.

Second, what's being split off may not be the problematic part.

For years, industry consolidation has subjected CVS and similar companies to dual pressures from regulators and consumers. Critics argue that these acquisitions create conflicts of interest between business lines and drive up U.S. healthcare spending—which is the highest in the world.

But this split is divesting the retail pharmacy stores, while the controversial combination of insurance and PBM remains in the same entity. Morningstar analyst Julie Utterback is particularly pointed: “In recent years, vertical integration by managed care organizations has drawn criticism from regulators and customers alike, and CVS has the biggest exposure to this model in the industry.” She believes, “Management likely felt it was better to take action now, in a relatively proactive manner, rather than wait for legislation or regulation to force their hand.”

In other words, this is a preemptive move, not a cure. Regulatory risk hasn’t disappeared because of the split—it’s just been reordered.

Third, splitting comes with a cost.

Two publicly listed, independent companies mean two sets of management teams, two sets of compliance and investor relations costs, and the loss of former cross-selling, centralized purchasing power, and backend sharing. CVS’s pharmacy network, Aetna’s insurance members, and Caremark’s prescription volume all previously reinforced each other; after the split, these “internal synergies” will become external negotiation costs—and the market currently has no data to assess whether this trade-off is worthwhile.

Fourth, while guidance beats consensus, it doesn't lead the industry.

Kevin Gade, Chief Operating Officer at Bahl & Gaynor, pointed out that the $8.65 guidance for 2027 isn’t particularly attractive compared to peers: some competitors are more focused on government-led healthcare programs, which—after Democrats decisively won control of Congress in Tuesday’s midterms—might receive more political support next year. This political shift on the same day undermined the relative value of CVS’s guidance.

Fifth, operational headwinds can't be split away.

Payment pressures on the pharmacy side persist, competition from Amazon and other online pharmacies continues, and the trend of prescription drug delivery reduces in-store traffic that drives ancillary sales—reflecting the increasing economic challenges faced by large U.S. pharmacy chains. On the insurance side, circumstances are similarly tough: post-pandemic, healthcare service usage has risen, and medical costs are high across Medicare, Medicaid, ACA plans, and commercial insurance business lines.

The company's own language was not optimistic: even as it raised its 2026 adjusted profit guidance to no less than $8.20 per share, CVS Health said it remains cautious about the rest of the year due to persistently high medical costs and other factors.

Sixth, the market has already heard this story.

Reuters previously reported that CVS Health considered several options—including a potential split—back in 2024, when the healthcare giant was grappling with multiple challenges across business lines. Expectations had already been priced in; so when the plan was finally announced, what was “fulfilled” was merely the question of “will there be a split,” not “how much value will a split unlock.”

Looking more broadly, this split is only the latest example of large-scale corporate break-ups in this decade. As splits become commonplace rather than exceptions, the narrative that “a split automatically unlocks value” is less likely to receive an automatic premium—markets now demand evidence, which CVS Health didn’t provide this time.

Industry benchmarks also aren’t encouraging. Competitor Walgreens, after a protracted sale process, sold off its Boots pharmacy business last year, and was itself acquired by private equity firm Sycamore Partners.

The market never pays for profits already realized, but for the structure of future cash flows. Until questions about how debt will be allocated, how capital will be deployed, and how much synergy will be lost are answered, this split plan is just a blueprint, not yet a valuation table. And a 12.5% drop is the price investors demanded for this blank space.